AR078352A1 - 5-(3,4-dicloro-fenil) -n- (2-hidroxi - ciclohexil) -6- (2,2,2 -trifluor-etoxi) nicotinamida y sales de la misma - Google Patents
5-(3,4-dicloro-fenil) -n- (2-hidroxi - ciclohexil) -6- (2,2,2 -trifluor-etoxi) nicotinamida y sales de la mismaInfo
- Publication number
- AR078352A1 AR078352A1 ARP100103303A ARP100103303A AR078352A1 AR 078352 A1 AR078352 A1 AR 078352A1 AR P100103303 A ARP100103303 A AR P100103303A AR P100103303 A ARP100103303 A AR P100103303A AR 078352 A1 AR078352 A1 AR 078352A1
- Authority
- AR
- Argentina
- Prior art keywords
- salts
- ciclohexil
- etoxi
- hidroxi
- dicloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Todas sus formas isomeras y las sales farmacéuticamente aceptables del mismo, a su obtencion, a las composiciones farmacéuticas que lo contienen y a su utilizacion como medicamento para el tratamiento y/o profilaxis de enfermedades que pueden tratarse con agentes que elevan el colesterol HDL, como son con preferencia la dislipidemia, la aterosclerosis y las enfermedades cardiovasculares. Reivindicacion 1: Un compuesto de la formula 1 las formas isomeras y las sales farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09170097 | 2009-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR078352A1 true AR078352A1 (es) | 2011-11-02 |
Family
ID=42830122
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100103303A AR078352A1 (es) | 2009-09-11 | 2010-09-09 | 5-(3,4-dicloro-fenil) -n- (2-hidroxi - ciclohexil) -6- (2,2,2 -trifluor-etoxi) nicotinamida y sales de la misma |
ARP180103371A AR114032A2 (es) | 2009-09-11 | 2018-11-16 | 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180103371A AR114032A2 (es) | 2009-09-11 | 2018-11-16 | 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma |
Country Status (35)
Country | Link |
---|---|
US (1) | US8227491B2 (es) |
EP (1) | EP2475645B1 (es) |
JP (1) | JP5604520B2 (es) |
KR (1) | KR101382871B1 (es) |
CN (1) | CN102639506B (es) |
AR (2) | AR078352A1 (es) |
AU (1) | AU2010294277B2 (es) |
BR (1) | BR112012005511B8 (es) |
CA (1) | CA2771493C (es) |
CL (1) | CL2012000611A1 (es) |
CO (1) | CO6491033A2 (es) |
CR (1) | CR20120089A (es) |
CY (1) | CY1114377T1 (es) |
DK (1) | DK2475645T3 (es) |
EC (1) | ECSP12011723A (es) |
ES (1) | ES2423821T3 (es) |
HK (1) | HK1172021A1 (es) |
HR (1) | HRP20130869T1 (es) |
IL (1) | IL217920A (es) |
IN (1) | IN2012DN00763A (es) |
MA (1) | MA33563B1 (es) |
MX (1) | MX2012002254A (es) |
MY (1) | MY161103A (es) |
NZ (1) | NZ597514A (es) |
PE (1) | PE20120863A1 (es) |
PL (1) | PL2475645T3 (es) |
PT (1) | PT2475645E (es) |
RS (1) | RS52987B (es) |
RU (1) | RU2541475C2 (es) |
SG (1) | SG179035A1 (es) |
SI (1) | SI2475645T1 (es) |
TW (1) | TWI412363B (es) |
UA (1) | UA107088C2 (es) |
WO (1) | WO2011029827A1 (es) |
ZA (1) | ZA201201599B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012031817A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US20120101282A1 (en) * | 2010-10-22 | 2012-04-26 | Pascal Dott | Process for the preparation of nicotinamide derivatives |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
WO2014180741A1 (en) * | 2013-05-06 | 2014-11-13 | F. Hoffmann-La Roche Ag | Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7 |
US20200085810A1 (en) | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
US11814354B2 (en) | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
CA2602787C (en) * | 2005-04-06 | 2013-12-24 | F. Hoffmann-La Roche Ag | Pyridine-3-carboxamide derivatives as cb1 inverse agonists |
AU2007304365A1 (en) | 2006-10-04 | 2008-04-10 | F. Hoffmann-La Roche Ag | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents |
-
2010
- 2010-08-09 UA UAA201204339A patent/UA107088C2/ru unknown
- 2010-09-03 US US12/875,196 patent/US8227491B2/en active Active
- 2010-09-08 TW TW099130367A patent/TWI412363B/zh active
- 2010-09-08 AU AU2010294277A patent/AU2010294277B2/en active Active
- 2010-09-08 PT PT107498735T patent/PT2475645E/pt unknown
- 2010-09-08 WO PCT/EP2010/063136 patent/WO2011029827A1/en active Application Filing
- 2010-09-08 PE PE2012000302A patent/PE20120863A1/es active IP Right Grant
- 2010-09-08 KR KR1020127008704A patent/KR101382871B1/ko active IP Right Grant
- 2010-09-08 PL PL10749873T patent/PL2475645T3/pl unknown
- 2010-09-08 JP JP2012528344A patent/JP5604520B2/ja active Active
- 2010-09-08 MX MX2012002254A patent/MX2012002254A/es active IP Right Grant
- 2010-09-08 MY MYPI2012001104A patent/MY161103A/en unknown
- 2010-09-08 IN IN763DEN2012 patent/IN2012DN00763A/en unknown
- 2010-09-08 SI SI201030327T patent/SI2475645T1/sl unknown
- 2010-09-08 BR BR112012005511A patent/BR112012005511B8/pt active IP Right Grant
- 2010-09-08 SG SG2012016127A patent/SG179035A1/en unknown
- 2010-09-08 DK DK10749873.5T patent/DK2475645T3/da active
- 2010-09-08 CA CA2771493A patent/CA2771493C/en active Active
- 2010-09-08 CN CN201080039932.7A patent/CN102639506B/zh active Active
- 2010-09-08 NZ NZ597514A patent/NZ597514A/xx unknown
- 2010-09-08 RU RU2012113924/04A patent/RU2541475C2/ru active
- 2010-09-08 ES ES10749873T patent/ES2423821T3/es active Active
- 2010-09-08 RS RS20130395A patent/RS52987B/en unknown
- 2010-09-08 EP EP10749873.5A patent/EP2475645B1/en active Active
- 2010-09-09 AR ARP100103303A patent/AR078352A1/es not_active Application Discontinuation
-
2012
- 2012-01-12 CO CO12004250A patent/CO6491033A2/es active IP Right Grant
- 2012-02-02 IL IL217920A patent/IL217920A/en active IP Right Grant
- 2012-02-21 CR CR20120089A patent/CR20120089A/es unknown
- 2012-03-02 ZA ZA2012/01599A patent/ZA201201599B/en unknown
- 2012-03-03 EC ECSP12011723 patent/ECSP12011723A/es unknown
- 2012-03-05 MA MA34662A patent/MA33563B1/fr unknown
- 2012-03-08 CL CL2012000611A patent/CL2012000611A1/es unknown
- 2012-12-12 HK HK12112824.3A patent/HK1172021A1/xx unknown
-
2013
- 2013-09-05 CY CY20131100768T patent/CY1114377T1/el unknown
- 2013-09-16 HR HRP20130869AT patent/HRP20130869T1/hr unknown
-
2018
- 2018-11-16 AR ARP180103371A patent/AR114032A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR114032A2 (es) | 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma | |
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
CL2018000119A1 (es) | Compuestos pirazolo[1,5-a]piridina sustituidos como inhibidores de quinasa de ret. | |
CY1122266T1 (el) | Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων | |
CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
CL2015003442A1 (es) | Derivados heterociclicos | |
CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
CL2012003178A1 (es) | Compuestos derivados de heterociclos nitrogenados insaturados o sus sales farmaceuticamente aceptables, como inhibidores de pde10; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades tales como psicosis, enfermedad de parkinson, depresion, trastornos del humor y demencia. | |
CR20160237A (es) | Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
CL2015001864A1 (es) | Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih. | |
CO6460766A2 (es) | Compuestos de haloalquil heteroaril benzamida | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
UY36056A (es) | “compuestos de heteroarilo o arilo bicíclicos fusionados “. | |
DOP2011000279A (es) | Derivados de benzofuranilo usados como inhibidores de glucoquinasa | |
UY35573A (es) | Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
CR20130629A (es) | Compuestos de 2-(2,4,5-anilino sustituido)pirimidina | |
UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
CL2012002497A1 (es) | Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras. | |
DOP2012000257A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
UY30267A1 (es) | Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones | |
AR077765A1 (es) | Inhibidores de los virus flaviviridae | |
UY33885A (es) | Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |